Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia

Atherosclerosis

Volumn 157, Issue 1, 2001, Pages 137-144

  Insull Jr , William ^a   Koren, Michael ^b   Davignon, Jean ^c   Sprecher, Dennis ^d   Schrott, Helmut ^e   Keilson, Leonard M ^f   Brown, Alan S ^g   Dujovne, Carlos A ^h   Davidson, Michael H ^h   McLain, Richard ⁱ   Heinonen, Therese ⁱ  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b Jacksonville Center for Clinical Research   (United States)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f MAINE MEDICAL CENTER   (United States)

^g Midwest Heart Research Foundation   (United States)

^h RADIANT RESEARCH   (United States)

ⁱ PFIZER INC   (United States)

Author keywords

ACAT; Atherosclerosis; Hyperlipidemia; Triglycerides

Indexed keywords

1 (2,6 DIISOPROPYL) 3 [[1 [4 (DIMETHYLAMINO)PHENYL]CYCLOPENTYL]METHYL]UREA; 1 BENZYL 1 [[3 (4 CHLOROPHENYL) 5 METHYL 2 BENZOFURANYL]METHYL] 3 (2,4,6 TRIFLUOROPHENYL)UREA; 2,2 DIMETHYL N (2,4,6 TRIMETHOXYPHENYL)DODECANAMIDE; 3 (2,4 DIFLUOROPHENYL) 1 HEPTYL 1 (4 NEOPENTYLBENZYL)UREA; ACA 147; APOLIPOPROTEIN B; AVASIMIBE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; E 5324; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LECIMIBIDE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N (2,6 DIISOPROPYLPHENYL)TETRADECYLTHIOACETAMIDE; PLACEBO; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPOLIPOPROTEINEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ACETATES; ADULT; AGED; ANTILIPEMIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; STEROL O-ACYLTRANSFERASE; SULFONIC ACIDS; TREATMENT OUTCOME;

EID: 0034965751     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00615-8     Document Type: Article

References (54)

1. Role of acyl-CoA:cholesterol acyltransferase in cellular cholesterol metabolism
2. Pharmacologic control of plasma cholesterol: Mechanisms of action of hypocholesterolemic agents
3. From phenotypes to genotypes: A remarkable quarter century: Dyslipidemia and atherosclerosis: A forecast of pharmaceutical approaches
4. Rat liver acyl-coenzyme A:cholesterol acyltransferase: Its regulation in vivo and some of its properties in vitro
5. Acyl-coenzyme A:cholesterol acyltransferase
6. Acyl-coenzyme A:cholesterol acyltransferase and hepatic apolipoprotein B secretion
7. Chemical modification of acyl-CoA-cholesterol acyltransferase. Identification of acyl-CoA-cholesterol acyltransferase sub-types by differential diethyl pyrocarbonate sensitivity
8. Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates
9. Acyl-coenzyme A:cholesterol acyltransferase 2
10. Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: An acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets
11. Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans
12. Effect of the acyl-CoA:cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans
13. The acyl-CoA:cholesterol acyltransferase (ACAT)-inhibitor avasimibe reduces atherosclerosis independently of its lipid-lowering effect in cholesterol-fed apoE3-Leiden transgenic mice
14. The ACAT inhibitor, avasimibe, reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits
15. The ACAT Inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters
16. Toxicity of CI-1011, a novel lipid regulating agent, in rats
17. Preclinical toxicology evaluation of CI-1011, an ACAT inhibitor, in beagle dogs
18. Clinical pharmacokinetics of CI-1011 an ACAT inhibitor
19. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
20. Assessing dietary adherence in the multiple risk factor intervention trial (MRFIT). I. Use of a dietary monitoring tool
21. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements
22. Standardization of micromethods for plasma cholesterol, triglyceride and HDL- cholesterol with the Lipid Clinic's methodology
23. Enzymatic determinations of cholesterol in high-density-lipoprotein fractions prepared by a precipitation technique
24. Comparison of an immunoprecipitation method for direct measurement of LDL-cholesterol with beta-quantification (ultracentrifugation)
25. International Federation of Clinical Chemistry Standardization project for measurements of apolipoproteins A-1 and B-II: Evaluation and selection of candidate reference materials
26. ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: An effect associated with enhanced intracellular degradation of ApoB
27. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs
28. Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet
29. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia
30. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
31. Plasma triglyceride and coronary heart disease
32. ACAT inhibitors as antiatherosclerotic agents: Compounds and mechanisms
33. Subacute toxicity of a novel inhibitor of acyl-CoA:cholesterol acyltransferase in beagle dogs
34. Difference between normal and WHHL rabbits in susceptibility to the adrenal toxicity of an acyl-CoA:cholesterol acyltransferase inhibitor, FR145237
35. Alpha-Substituted malonester amides: Tools to define the relationship between ACAT inhibition and adrenal toxicity
36. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase
37. ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet. Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance
38. In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT
39. Pharmacological properties of a novel ACAT inhibitor (CP-113,818) in cholesterol-fed rats, hamsters, rabbits, and monkeys
40. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461
41. TMP-153, a novel ACAT inhibitor, inhibits cholesterol absorption and lowers plasma cholesterol in rats and hamsters
42. Anti-atherosclerotic effect of E5324, an inhibitor of acyl-CoA:cholesterol acyltransferase, in Watanabe heritable hyperlipidemic rabbits
43. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis
44. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases
45. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis
46. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina
47. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
48. Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells
49. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation
50. ACA-147: An inhibitor of ACAT and of the oxidative modification of LDL
51. HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits
52. Effect of FR 145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall